We investigated the safety and efficacy of stereotactic radiosurgery (SRS) for 46 patients with melanoma brain metastases who also received ipilimubab (Ipi). Patients treated with SRS during or before Ipi had better overall survival (PZ.008) and less regional recurrence (PZ.003) than did those treated with SRS after Ipi. Many also had a temporary increase in tumor size, possibly because of an enhanced immunomodulatory effect. Overall, the Purpose: Ipilimumab (Ipi), a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, has been shown to improve survival in patients with metastatic melanoma. In this single-institution study, we investigated the safety and efficacy of stereotactic radiosurgery (SRS) for patients with melanoma brain metastases (BMs) who also received Ipi. Methods and Materials: From 2005 to 2011, 46 patients with melanoma received Ipi and underwent single-fraction SRS for BMs. A total of 113 BMs (91% intact, 9% postoperative) were treated with a median dose of 21 Gy (range, 15-24 Gy). Ipi was given at 3 mg/kg (54%) or 10 mg/kg (46%) for a median of 4 doses (range, 1-21). Adverse events were recorded with the use of the Common Terminology Criteria for Adverse Events 3.0. Kaplan-Meier methods were used to estimate survival, and Cox regression was used to investigate associations. Results: Fifteen patients received SRS during Ipi, 19 received SRS before Ipi, and 12 received SRS after Ipi. Overall survival (OS) was significantly associated with the timing of SRS/Ipi (PZ.035) and melanoma-specific graded prognostic assessment (PZ.013). Patients treated with SRS during or before Ipi had better OS and less regional recurrence than did those treated with SRS after Ipi (1-year OS 65% vs 56% vs 40%, PZ.008; 1-year regional recurrence 69% vs 64% vs 92%, PZ.003). SRS during Ipi also yielded a trend toward less local recurrence than did SRS before or after Ipi (1-year local recurrence 0% vs 13% vs 11%, PZ.21). On magnetic resonance imaging, an increase in BM diameter to >150% was seen in 50% of patients treated during or before Ipi but in only 13% of patients treated after Ipi. Grade 3 to 4 toxicities were seen in 20% of patients. Conclusion: Overall, the combination of Ipi and SRS appears to be well tolerated. Concurrent delivery of Ipi and SRS is associated with favorable locoregional control and possibly longer survival. It may also cause a temporary increase in tumor size, possibly because of an enhanced immunomodulatory effect. Ó
Summary
We investigated the safety and efficacy of stereotactic radiosurgery (SRS) for 46 patients with melanoma brain metastases who also received ipilimubab (Ipi). Patients treated with SRS during or before Ipi had better overall survival (PZ.008) and less regional recurrence (PZ.003) than did those treated with SRS after Ipi. Many also had a temporary increase in tumor size, possibly because of an enhanced immunomodulatory effect. Overall, the Purpose: Ipilimumab (Ipi), a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, has been shown to improve survival in patients with metastatic melanoma. In this single-institution study, we investigated the safety and efficacy of stereotactic radiosurgery (SRS) for patients with melanoma brain metastases (BMs) who also received Ipi. Methods and Materials: From 2005 to 2011, 46 patients with melanoma received Ipi and underwent single-fraction SRS for BMs. A total of 113 BMs (91% intact, 9% postoperative) were treated with a median dose of 21 Gy (range, 15-24 Gy). Ipi was given at 3 mg/kg (54%) or 10 mg/kg (46%) for a median of 4 doses (range, . Adverse events were recorded with the use of the Common Terminology Criteria for Adverse Events 3.0. Kaplan-Meier methods were used to estimate survival, and Cox regression was used to investigate associations. Results: Fifteen patients received SRS during Ipi, 19 received SRS before Ipi, and 12 received SRS after Ipi. Overall survival (OS) was significantly associated with the timing of SRS/Ipi (PZ.035) and melanoma-specific graded prognostic assessment (PZ.013). Patients treated with SRS during or before Ipi had better OS and less regional recurrence than did those treated with SRS after Ipi (1-year OS 65% vs 56% vs 40%, PZ.008; 1-year regional recurrence 69% vs 64% vs 92%, PZ.003). SRS during Ipi also yielded a trend toward less local recurrence than did SRS before Introduction Ipilimumab (Ipi), a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), allows for T cell activation and proliferation, thereby enhancing immune response to cancer. In patients with metastatic melanoma, Ipi has been shown to improve overall survival (OS) in 2 phase 3 trials, 1 trial in comparison with the cancer vaccine gp100 and the other in combination with dacarbazine (1, 2). These trials led to the approval of Ipi by the U.S. Food and Drug Administration in 2011.
As many as 60% of patients with metastatic melanoma will experience brain metastases (BMs), and those with relatively good prognosis and few BMs often undergo treatment with stereotactic radiosurgery (SRS) (3-7). The rationale for combining Ipi and SRS is based on potential activity of Ipi in the brain, as demonstrated by Margolin et al (8) in a phase 2 trial, and on the possible abscopal effects of SRS that may enhance the systemic response to Ipi (8) (9) (10) (11) (12) (13) (14) . Several series have reported promising preliminary results with the combination of SRS and Ipi, including a study by Knisely et al (5) showing median OS of 21.3 months in 27 patients (15) (16) (17) (18) . Given our large institutional experience with Ipi and SRS, we conducted a retrospective study to investigate the safety and efficacy of this combination for treatment of melanoma BMs.
Methods and Materials
From an institutional melanoma database, 46 patients were identified who received Ipi and underwent single-fraction SRS for melanoma BMs between 2005 and 2011. Most of these patients (85%) received Ipi as part of a research protocol. Ipi was delivered intravenously every 3 weeks for 4 doses during the induction phase. After induction, 13 patients (28%) received maintenance therapy every 3 months.
Gadolinium-enhanced T1-weighted magnetic resonance imaging (MRI) with 3-mm slices was performed before SRS. On the day of treatment, patients were immobilized with a stereotactic frame. Contrast-enhanced simulation computed tomography with 2-mm slices was performed, and the BrainLAB system was used for treatment planning. The radiation dose (15-24 Gy) was prescribed based on the size of the lesion and its proximity to other structures. Typically, 10 noncoplanar static beams were delivered. Dose was prescribed to the 80% isodose line. Quality criteria and plan evaluation were completed according to the guidelines of the Radiation Therapy Oncology Group (19) .
Toxicities were recorded by use of the Common Terminology Criteria for Adverse Events (CTCAE) 3.0. During routine follow-up, patients were assessed with MRI 6 to 8 weeks after SRS, then every 3 months thereafter. All MRIs were evaluated for tumor size (maximum axial diameter), hemorrhage, and recurrence. The melanomaspecific graded prognostic assessment score (mGPA) was calculated for each patient based on Karnofsky performance status (KPS) and the number of BMs. This is a validated prognostic score of 0 to 4 (best) that predicts the survival of patients with melanoma BMs (4).
Kaplan-Meier methods were used to estimate OS, local control, and regional control. OS was analyzed per patient, from date of diagnosis of BMs to date of death or last patient contact. Local and regional recurrence-free survival were analyzed per treated lesion, from date of SRS to date of recurrence or last MRI examination. Local recurrence was defined as brain recurrence within the SRS field, and regional recurrence was defined as brain recurrence outside the SRS field. Cox regression was used to investigate the association of variables with outcomes. Three groups were compared on the basis of timing of therapies: patients who received SRS before the first dose of Ipi ("SRS before Ipi"), patients who received SRS between doses of Ipi or <1 month after the last dose of Ipi ("SRS during Ipi"), and patients who received SRS >1 month after the last dose of Ipi ("SRS after Ipi").
Results

Patient and tumor characteristics
This study included 46 patients with metastatic melanoma who received Ipi and SRS for BMs between 2005 and 2011. The patient, tumor, and treatment characteristics are shown in Table 1 . The median age was 57 years (range, 24-76 years), and the male:female ratio was 1.4:1. The median mGPA was 3 out of 4, because most patients had KPS 90% and 1 to 2 BMs (4). Only 37% of patients had elevated lactate dehydrogenase. Almost all patients had other nonbrain metastasea and underwent prior systemic therapy, including temozolomide in 46%, interleukin-2 in 15%, and cisplatin, vinblastine, and temozolomide in 37%. No patients received vemurafenib.
Most of the BMs were small and asymptomatic, with a median axial diameter of 0.8 cm (range, 0.2-2.9 cm). The median interval from diagnosis of BMs to date of SRS was <1 month. Only 9% of patients underwent brain surgery before SRS. Only 1 patient had whole brain radiation therapy (WBRT) immediately after SRS, whereas 9 had WBRT after locoregional recurrence. A total of 113 BMs were treated with SRS with a median dose of 21 Gy (range, 15-24 Gy). Most patients (83%) received a short course of prophylactic steroids with SRS (typically 4 mg dexamethasone for 2 days).
Ipilimumab dosing was 3 mg/kg in 54% and 10 mg/kg in 46%, with a median total of 4 doses (typical induction). Fifteen patients received SRS during Ipi, including 8 between induction doses, 4 within 1 month after the last induction dose, and 3 between doses of protocol-allowed maintenance. Nineteen patients received SRS before Ipi, with a median of 3 months between SRS and the first dose of Ipi (range, 1-39 months). Twelve patients received SRS after Ipi, with a median of 2 months between the last dose of Ipi and SRS (range, 1-32 months). Notably, there were no significant differences among these timing groups for any patient characteristics in Table 1 .
The median OS for all patients was 12.4 months (range, 2-89 months). Twelve of 46 patients are still alive at the time of analysis, with a median follow-up time for survivors of 22 months (range, 6-89 months). The survivors include 6 patients in the SRS during Ipi group, 4 in the SRS before Ipi group, and 1 in the SRS after Ipi group. On multivariate Cox regression analysis, OS was associated with the timing of SRS and Ipi (PZ.035) and melanomaspecific GPA (PZ.013) but not age, KPS, lactate dehydrogenase, or dose of Ipi. On univariate analysis, patients treated with SRS during or before Ipi had better OS than did those treated with SRS after Ipi (1-year OS 65% vs 56% vs 40%; PZ.008) (Fig. 1A) . Patients with higher mGPA also had improved OS, and the median survival of patients in the present cohort was longer than those in the Sperduto et al (4) study of mGPA (Table 2) . Notably, the following variables were also tested but were not significantly associated with OS on univariate analysis: SRS dose, number of Ipi treatments, number of BMs, prior systemic therapy, and prior surgical resection.
Local control (within the SRS field) was high in all groups (Fig. 1B) , as expected based on previous studies of melanoma BMs treated with SRS alone (6) . There was a trend toward improved local control in the SRS during Ipi group (1-year local recurrence 0%) compared with the SRS before Ipi (13%) or SRS after Ipi (11%) groups (PZ.21). The size of BMs was not associated with local control in this series. Out-of-field (regional) brain recurrences occurred in almost all patients receiving SRS after Ipi (1-year regional recurrence 92%) compared with significantly fewer patients receiving SRS during Ipi (69%) or before Ipi (64%; PZ.003) (Fig. 1C) . Table 3 shows adverse events according to CTCAE 3.0, with emphasis on patients receiving SRS during Ipi. Grade 3 to 4 adverse events were present in only 20% of patients, and there were too few events to analyze statistically. SRS did not exacerbate the typical systemic immune-related adverse events associated with Ipi such as enterocolitis, pruritus, and hepatitis. Central nervous system toxicities were slightly more frequent in patients receiving SRS during Ipi, as discussed later. However, adverse events did not interfere with the completion of planned Ipi in any patients.
On follow-up MRIs, the maximum axial diameter of treated tumors increased to >150% of pre-SRS size in 50% of patients treated with SRS during or before Ipi, compared with only 13% of those treated with SRS after Ipi. Notably, for patients treated with SRS before Ipi, tumors did not increase in size until Ipi was started, often months after the completion of SRS. Imaging findings were consistent with hemorrhagic products, edema, or both in 82% of these patients and were concerning for local recurrence in only 18%. The presence of hemorrhagic products was particularly common after SRS during Ipi (40%), and some of these patients experienced headache, seizure, temporary cognitive or neurologic change, or a combination of these effects, as shown in Table 3 . However, the majority of patients were asymptomatic. Overall, only 11 patients (24%) required steroid treatment for more than 2 weeks, including 5 patients in the SRS during Ipi group (31%). Most of the lesions subsequently contracted without further treatment, but 11 were resected for suspected recurrence or progression. Surprisingly, in 5 of these cases, pathologic examination showed complete necrosis and lymphocytic/ histiocytic inflammation with no viable tumor ( Fig. 2A) . The remaining lesions showed components of viable melanoma admixed with necrosis, inflammation, or both. Previous reports have suggested a possible abscopal effect of stereotactic body radiation inducing an enhanced systemic response to Ipi (11) (12) (13) (14) . This study was not designed to investigate whether brain SRS may induce an abscopal effect in combination with Ipi. However, anecdotally there was 1 patient with possible abscopal effect 
Discussion
This retrospective, single-institution study is the largest series to date investigating the combination of brain SRS and Ipi immunotherapy for patients with melanoma BMs (nZ46 patients). Our results suggest several important hypotheses. First, delivery of SRS during or before Ipi may yield comparatively favorable survival and regional control compared with delivery of SRS after Ipi. These effects clearly need to be investigated further. Second, SRS during or before Ipi may cause a temporary increase in tumor size resulting from local inflammation or hemorrhage. Finally, the combination of Ipi and SRS appears to be safe and well tolerated in patients with melanoma BMs. Our study demonstrated favorable OS (median, 12.4 months) when compared with previous studies of patients with melanoma BMs treated with SRS alone or Ipi alone, with caveats noted for cross-trial comparison. Sperduto et al (4) recently validated the melanoma-specific GPA as a prognostic tool for patients with melanoma BMs (nZ481; treated in 1993-2010). For the subset of patients who received SRS alone (nZ221), Sperduto et al (4) reported a median OS of 7.3 months (compared with 2.9 months for WBRT alone and 6.7 months for all patients). Our results confirmed the importance of mGPA as a prognostic factor but showed consistently longer survival for each mGPA score than expected (Table 2 ). In a recent phase 2 trial by Margolin et al (8) , patients with melanoma BMs were treated with Ipi alone (nZ72; treated in 2008-2009), with only 8% receiving SRS and 33% receiving WBRT. The median survival for asymptomatic patients who received Ipi was 7.0 months, again less than observed in our study. Notably, this multi-institutional phase 2 study included patients from our institution treated in the same time period. Several other series have reported promising preliminary results with the combination of SRS and Ipi, including a study by Knisely et al (5) showing extended survival in 27 patients receiving SRS plus Ipi (21.3 months) versus 50 patients receiving SRS alone (4.9 months) (15) (16) (17) (18) .
Patients with melanoma BMs typically have high rates of regional (brain) recurrence and thus a high risk of neurologic death (20) (21) (22) . SRS and surgery have excellent rates of local control but high rates of regional recurrence requiring subsequent courses of treatment (5, 21, 22 ). In the current study, patients in the SRS after Ipi group had 92% regional recurrence within 1 year, but those in the SRS during Ipi or before Ipi groups had only 69% and 64% regional recurrence, respectively. This suggests that Ipi may have regional immunomodulatory effects in the brain. It is possible that antibodies such as Ipi may be able to penetrate melanoma BMs if the bloodebrain barrier is disrupted, but even if Ipi is unable to penetrate, previous reports have shown infiltration of activated T cells in BMs after treatment with Ipi (23) .
The results of this study suggest that the combination of SRS and Ipi may yield increased BM size, possibly caused by inflammation. This phenomenon of lesion expansion during immunotherapy has been well described (24) . Indeed, systemic Ipi responses are often characterized by initial stable or increased lesion size, followed by delayed contraction, prompting the need for new immune-related response criteria (25) . In our study, imaging frequently showed a temporary increase in the size of lesions after treatment with SRS during Ipi, often associated with hemorrhage or edema, followed by gradual contraction suggestive of subacute inflammatory response. In patients receiving SRS before Ipi, there was a similar temporary increase in BM size, but this did not occur until after Ipi was started, often months after the completion of SRS. This timing suggests that local inflammation was not just a response to SRS but might reflect the local immunomodulatory effects of Ipi. Without Ipi, Huber et al (26) reported transient increases in BM size after SRS in only 12% of patients. The appearance of these treated lesions on MRI may raise a suspicion for recurrence, but in many cases close observation may be appropriate rather than surgical resection. Indeed, we found that 5 of 11 lesions that were resected for suspected recurrence showed 100% necrosis on pathologic examination (Fig. 2A) .
Many of the patients in the study who had local inflammation or bleeding after SRS were asymptomatic, but several had associated headaches, seizures, or temporary cognitive or neurologic change (Table 3) . Other commonly observed side effects from Ipi included immunemediated effects such as pruritus, rash, enterocolitis, and fatigue (27) . These findings highlight the unique spectrum of toxicities seen with immunotherapies, and the importance of caution when they are administered in combination with other therapies. Overall, the combination of Ipi and SRS appeared to be well tolerated and safe, with grade 3 to 4 toxicities in only 20% of patients, but this needs to be verified in a larger prospective study. Only 11% of patients required steroid treatment for more than 2 weeks, and the authors no longer recommend prophylactic steroids for patients with small asymptomatic lesions, especially because steroids could potentially counteract the effectiveness of Ipi (8) .
An important remaining question is whether singlefraction brain SRS may induce an abscopal effect enhancing the systemic response to Ipi. The current study was not designed to answer this question, and although a single case showed timing suggestive of an abscopal effect, there were no immunologic correlates to support this hypothesis. However, the improved OS and regional brain control seen in patients receiving SRS before and during Ipi, along with the increased local inflammation, do suggest an interaction between radiation and Ipi. Although speculative, the release of antigens from dying melanoma cells after SRS may help Ipi to prime the immune response. When SRS is given long after Ipi, these effects would not be expected. An increasing number of researchers are now investigating this interaction (especially with large radiation dose per fraction), and preliminary results show possible mediation by activated T cells, antitumor antibodies, or both (9-11, 28, 29) .
The limitations of this study include its retrospective nature and the small number of patients, although it is the largest series investigating the combination of SRS and Ipi for melanoma BMs. Our relatively favorable results with prolonged OS may be partly because most of these patients were on protocol and received screening MRIs and close follow-up, which could result in lead-time bias. There could also have been selection bias affecting the comparison of SRS timing groups, given that the patients receiving SRS after Ipi may have had previous progression or lack of response to Ipi, predisposing them to worse outcomes. Additionally, 3 patients in the SRS during Ipi group received SRS during maintenance Ipi. Given that only patients with stable disease or response are generally candidates for maintenance therapy, this may have contributed to the favorable OS in this group. Overall, these data must be considered as hypothesis generating rather than hypothesis testing. However, in the absence of larger prospective studies, the results may inform patient care by suggesting that the combination of Ipi and SRS is relatively safe. To further investigate safety, several institutions are currently conducting prospective studies of Ipi and brain radiation for patients with melanoma BMs (NCT01703507 and NCT01950195).
Conclusion
This largest-to-date single-institution retrospective study investigated the safety and efficacy of SRS in 46 patients with melanoma BMs who also received Ipi immunotherapy. We found that delivery of SRS during or before Ipi was associated with comparatively favorable survival and regional control compared with delivery of SRS after Ipi. However, SRS during or before Ipi may also be associated with a temporary increase in size or hemorrhage of the irradiated lesion. Overall, the combination of Ipi and SRS appears to be safe and well tolerated.
